ANTX

The company reported its third-quarter 2025 financial results, announced a research collaboration with GSK for tuberculosis, and received a third year of funding from the Gates Foundation on November 12, 2025. On March 3, 2026, AN2 Therapeutics announced its plans to advance oral epetraborole into a Phase 2 study for polycythemia vera (PV). The company announced a $40 million private placement financing on March 9, 2026. On March 17, 2026, AN2 Therapeutics reported its fourth-quarter and full-year 2025 financial results, highlighting progress in its business and scientific endeavors. The company announced the initiation of a Phase 2 investigator-initiated clinical trial of epetraborole for Mycobacterium abscessus Complex Lung Disease on March 31, 2026. AN2 Therapeutics established a new $80 million at-the-market (ATM) stock sale facility with Jefferies, simultaneously terminating a previous ATM program on April 9, 2026. The company announced its participation in the 2026 Stifel Virtual Targeted Oncology Forum on May 7, 2026. Over the past year, AN2 Therapeutics' stock price has experienced significant growth.